Solid Biosciences Inc.

- Obtaining Orphan designation from the European Commission reflects Solid's commitment to the global development of SGT-212 for individuals living with Friedreich's ataxia - - SGT-212 is a first-in-class dual route FA gene therapy designed to combine direct, MRI-guided delivery to the dentate nuclei with systemic delivery to reach cardiac and other systemic tissues - - Five participants have been dosed in the ongoing Phase 1b FALCON clinical trial and SGT-212 has been well tolerated as of October 5, 2026 - - Solid expects to report initial FALCON clinical data in Q1 2027 - CHARLESTOWN, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the European Commission (EC), acting upon the positive opinion of the European Medicines Agency's Committee for Orphan Medicinal Products, has granted Orphan designation to SGT-212 for the treatment of Friedreich's ataxia (FA).

Solid Biosciences (NASDAQ: SLDB - Get Free Report) is projected to post its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings report for the latest details

CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that seven abstracts have been accepted for poster presentation at the 33rd European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany.

CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,150 restricted stock units (“RSUs”) to one newly hired employee.